



WEDNESDAY, 14th NOVEMBER 2018 COMMENCING 09:30 AM
AT THE PARK INN HOTEL CARDIFF NORTH, CIRCLE WAY EAST
LLANEDEYRN, CARDIFF, CF23 9XF

AGENDA

- | | |
|---------------------------------------|------------------|
| 1. Welcome and introduction | Enclosure |
| 2. Apologies | |
| 3. Declarations of interest | |
| 4. Minutes of previous meeting | 1/AWMSG/1118 |

To protect commercial confidentiality the following appraisals will be held in private

- | | |
|--|----------------------------|
| 5. Appraisal 1: Full Submission (WPAS)
Bictegravir/emtricitabine/tenofovir alafenamide (Biktarvy®) for the treatment of adults infected with human immunodeficiency virus 1 without present or past evidence of viral resistance to the integrase inhibitor class, emtricitabine or tenofovir | 2/AWMSG/1118
Appendices |
|--|----------------------------|

The meeting will now open to the public for the committee decisions

- | | |
|---|----------------------------|
| 6. Chairman's report (verbal update) | |
| 7. Appraisal 2: Limited Submission
Fosaprepitant (Ivemend®) for the prevention of nausea and vomiting associated with highly and moderately emetogenic cancer chemotherapy in patients aged 6 months to less than 18 years of age. Fosaprepitant is given as part of a combination therapy | 3/AWMSG/1118
Appendices |
| 8. Appraisal 3: Limited Submission
Tiotropium (Spiriva® Respimat®) as add-on maintenance bronchodilator treatment in patients aged 6 years to <18 years with severe asthma who experienced one or more severe asthma exacerbations in the preceding year | 4/AWMSG/1118
Appendices |

Date of next meeting – Wednesday, 12th December 2018 in Cardiff